pancreatic hormone
Glucagon dose
Answer
FDA label for Glucagon: The recommended dosage is 1 mg (1 mL) injected subcutaneously or intramuscularly into the upper arm, thigh, or buttocks, or intravenously. ■ If there has been no response after 15 minutes, an additional 1 mg dose (1 mL) may be administered while waiting for emergency assistance. Half-life on the label: approximately 35 minutes. Trials with posted results tested 1 dose, most often 1 mg.
Not dosing advice.
FDA LABEL
What the approved labels state
Glucagon ANDA208086 · label of 2026-08-11 Regulator
The recommended dosage is 1 mg (1 mL) injected subcutaneously or intramuscularly into the upper arm, thigh, or buttocks, or intravenously. ■ If there has been no response after 15 minutes, an additional 1 mg dose (1 mL) may be administered while waiting for emergency assistance.
Gvoke VialDx NDA212097 · label of 2026-07-07 Regulator
Recommended dose for adult and pediatric patients aged 12 years of age and older is 1 mg.
Baqsimi NDA210134 · label of 2026-06-19 Regulator
The recommended dose of BAQSIMI is 3 mg administered as one actuation of the intranasal device into one nostril.
Half-life: approximately 35 minutes (section 12.3).
Gvoke HypoPen 0.5 mg Auto-Injector NDA212097 · label of 2025-12-23 Regulator
Recommended dose for adult and pediatric patients aged 12 years of age and older is 1 mg.
IN TRIALS
Doses tested in 319 trials with posted results
| Dose in the arm title | Trials | People on it | Phases |
|---|---|---|---|
| 1 mg | 1 | 28 | 2 |
Trial register Read from the titles of arms that received Glucagon (n ≥ 20). An arm naming several doses counts under each; a schedule or escalation is on the trial record. All trials.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.